

## OTC Obesity - Poland

URL:	<a href="https://marketpublishers.com/r/OB22C83517AEN.html">https://marketpublishers.com/r/OB22C83517AEN.html</a>
Date:	April 23, 2010
Pages:	35
Price:	US\$ 990.00
ID:	OB22C83517AEN

2009 was the first year that OTC obesity gained a presence in Poland. In April 2009 GlaxoSmithKline Pharmaceuticals SA launched the first orlistat-based OTC obesity product under the Alli brand name. 2009 value sales reached more than PLN4 million.

Euromonitor International's OTC Obesity Products in Poland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

### Product coverage:

**Data coverage:** market sizes (historic and forecasts), company shares, brand shares and distribution data.

### Why buy this report?

- Get a detailed picture of the Consumer Health industry;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market's major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

## Table of Content

### Executive Summary

Continued Sales Growth Despite Economic Slowdown

Poles Becoming Increasingly Health-conscious

Multinational Companies Prove Strong Opponents

Chemists/pharmacies Remains Core Distribution Channel

Further Growth in Consumer Healthcare Expected

Key Trends and Developments

Health and Wellness Trend Boosts Sales

Lifestyle Changes Shape Consumer Behaviour

Growing Focus on Looking Good Shapes Sales

Domestic Companies Fight Back

Targeted Product Developments Fuel Growth

Market Indicators

Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009

## Table 2 Life Expectancy at Birth 2004-2009

## Market Data

Table 3 Sales of Consumer Health by Sector: Value 2004-2009

Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009

Table 5 Consumer Health Company Shares by Value 2005-2009

Table 6 Consumer Health Brand Shares by Value 2006-2009

Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009

Table 8 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009

Table 9 Forecast Sales of Consumer Health by Sector: Value 2009-2014

Table 10 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014

## Appendix

## OTC Registration and Classification

## Vitamins and Dietary Supplements Registration and Classification

## Self-medication/self-care and Preventative Medicine

## Switches

Summary 1 OTC Healthcare Switches 2007-2009

## Definitions

## Sector and Subsector Definitions

Summary 2 Research Sources

## Apipol-farma Sp Zoo

## Strategic Direction

## Key Facts

Summary 3 Apipol-Farma Sp zoo: Key Facts

Summary 4 Apipol-Farma Sp zoo: Operational Indicators

## Company Background

## Production

## Competitive Positioning

Summary 5 Apipol-Farma Sp zoo: Competitive Position 2009

## Herbapol Lublin SA

## Strategic Direction

## Key Facts

Summary 6 Herbapol Lublin SA: Key Facts

Summary 7 Herbapol Lublin SA: Operational Indicators

## Company Background

## Production

## Competitive Positioning

Summary 8 Herbapol Lublin SA: Competitive Position 2009

## Polpharma SA

## Strategic Direction

## Key Facts

Summary 9 Polpharma SA: Key Facts

Summary 10 Polpharma SA: Operational Indicators

## Company Background

## Production

Summary 11 Polpharma SA: Production Statistics 2009

## Competitive Positioning

Summary 12 Polpharma SA: Competitive Position 2009

## Polski Lek SA

## Strategic Direction

## Key Facts

Summary 13 Polski Lek SA: Key Facts

## Company Background

## Production

## Competitive Positioning

Summary 14 Polski Lek SA: Competitive Position 2009

Ppf Hasco-lek SA

Strategic Direction

Key Facts

Summary 15 PPF Hasco-Lek SA: Key Facts

Summary 16 PPF Hasco-Lek SA: Operational Indicators

Company Background

Production

Competitive Positioning

Summary 17 PPF Hasco-Lek SA: Competitive Position 2009

Trends

Category Data

Table 11 Sales of OTC Obesity: Value 2009

Table 12 OTC Obesity Company Shares by Value 2005-2009

Table 13 OTC Obesity Brand Shares by Value 2006-2009

Table 14 Forecast Sales of OTC Obesity: Value 2009-2014

Table 15 Forecast Sales of OTC Obesity: % Value Growth 2009-2014

### I would like to order:

**Product name:** OTC Obesity - Poland  
**Product link:** <https://marketpublishers.com/r/OB22C83517AEN.html>  
**Product ID:** OB22C83517AEN  
**Price:** US\$ 990.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/OB22C83517AEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**